Globus Medical, Inc. (NYSE:GMED) Given Average Rating of “Moderate Buy” by Brokerages

Globus Medical, Inc. (NYSE:GMED) has received a consensus rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $106.3636.

Several research analysts have weighed in on GMED shares. Barclays boosted their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Royal Bank Of Canada upped their price target on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday. TD Cowen raised Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Finally, Needham & Company LLC upped their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday.

Insider Activity at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 18.38% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. William Blair Investment Management LLC grew its holdings in shares of Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after purchasing an additional 414,134 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in shares of Globus Medical by 49,020.3% during the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock worth $51,034,000 after purchasing an additional 889,229 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Globus Medical by 189.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 476,531 shares of the medical device company’s stock worth $27,953,000 after purchasing an additional 312,149 shares in the last quarter. Foresight Group Ltd Liability Partnership grew its holdings in shares of Globus Medical by 160.7% during the third quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock worth $24,142,000 after purchasing an additional 259,870 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Globus Medical during the third quarter worth about $539,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

Globus Medical Trading Down 8.5%

GMED stock opened at $77.81 on Friday. The stock’s fifty day simple moving average is $89.86 and its two-hundred day simple moving average is $86.65. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The stock has a market cap of $10.52 billion, a P/E ratio of 18.10, a P/E/G ratio of 1.99 and a beta of 1.00.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.69% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. The business’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts forecast that Globus Medical will post 4.46 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.